Sort
3,198 grants matching “mrna vaccine”
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
$1,549,397Charles Bix Shoemaker · Tufts University Boston · R01 · FY2025 · AI
Natural History of HPV Infection to Neoplasia
$1,543,996Anna-Barbara None Moscicki · University Of California, San Francisco · R37 · FY2007 · CA
Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis
$1,542,693Paul Stephen Keim · Northern Arizona University · U19 · FY2023 · AI
Vector-Borne Diseases: Biology Of Vector Host Relationship
$1,536,766Jose M Ribeiro · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI
DNA Vaccines
$1,533,961George N. Pavlakis · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Natural History of HPV Infection to Neoplasia
$1,532,397Anna-Barbara None Moscicki · University Of California, San Francisco · R37 · FY2008 · CA
Antigen Processing And Presentation In The Intestine
$1,531,480Brian Kelsall · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis
$1,530,461Paul Stephen Keim · Northern Arizona University · U19 · FY2025 · AI
mVACS--mRNA Vaccines for C. difficile Suppression
$1,529,954Frederic D Bushman · University Of Pennsylvania · U19 · FY2024 · AI
mVACS--mRNA Vaccines for C. difficile Suppression
$1,529,954Frederic D Bushman · University Of Pennsylvania · U19 · FY2023 · AI
mVACS--mRNA Vaccines for C. difficile Suppression
$1,529,954Frederic D Bushman · University Of Pennsylvania · U19 · FY2025 · AI
NIAID- VRC- Evaluating mRNA Vaccine Candidates and Capability Development
$1,527,328Barry Gause · Leidos Biomedical Research, Inc. · N01 · FY2022 · AI
Laboratory And Pre-clinical Studies Of Parainfluenza Viruses
$1,520,063Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI
Immunotherapeutic Approaches for AIDS
$1,519,604George N. Pavlakis · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Early in vivo Expressed Antigens and their Role in Virulence, Immune Response, and Vaccines for Coccidioidomycosis
$1,519,099Paul Stephen Keim · Northern Arizona University · U19 · FY2022 · AI
Antigen Processing And Presentation In The Intestine
$1,512,590Brian Kelsall · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
Immunotherapeutic Approaches for AIDS
$1,511,661George N. Pavlakis · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
RNA TRASFECTED DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY
$1,508,679Duke University · P01 · FY2001 · CA
Delivery of biologically active nucleic acids to epidermal cells
$1,503,903Roger L Kaspar · Transderm, Inc. · RC2 · FY2009 · AR
Fox COBRE Phase II Admin Core
$1,498,202Joseph M Fox · University Of Delaware · P20 · FY2023 · GM
RNA TRASFECTED DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY
$1,497,862Duke University · P01 · FY2002 · CA
Heterodimeric IL-15 in Cancer Immunotherapy
$1,489,039George N. Pavlakis · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Discovery and characterization of programmable biological systems
$1,485,000Jonathan Strecker · Massachusetts General Hospital · DP2 · FY2025 · HL
DNA Vaccines
$1,483,911George N. Pavlakis · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Emory Vaccine and Treatment Evaluation Unit - KidCOVE
$1,475,091Nadine Georges Rouphael · Emory University · UM1 · FY2021 · AI